1. Pink Sheet
  2. >>Product Reviews
  3. >>EU CHMP

EU Decision Time For Topical Gene Therapy Beremagene Geperpavec And Five Others

 
• By Eliza Slawther

The European Medicines Agency is set to issue opinions this week on whether pan-EU marketing approval should be granted to a number of new products.

Several products could get a thumbs up or down from the EMA this week (Shutterstock)

Beremagene geperpavec, Krystal Biotech’s topical gene therapy for the rare genetic skin disorder, dystrophic epidermolysis bullosa (DEB), is among the products that European Medicines Agency might this week recommended for marketing approval across the EU.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from EU CHMP

More from Geography

Brazil’s ANVISA Clarifies Registration Procedures For Biologicals

 
• By Francesca Bruce

Brazil’s drug regulator has published a new technical note updating guidelines on registration and post-registration procedures for biological products.

SpringWorks To Make Its Case For Nirogacestat At High-Stakes EMA Meeting

 
• By Francesca Bruce

Nirogacestat was one of four products scheduled for an oral explanation meeting at the European Medicines Agency this week.

Postmarketing Surprise Is Latest Plot Twist For Novavax’s COVID-19 Vaccine BLA

 
• By Bridget Silverman

Three weeks after its user fee goal date, the FDA demanded a postmarketing commitment “to generate additional data,” Novavax said.